2118899-51-5
Chemical Structure
Taragarestrant
Synonym(s): D-0502
- CAS No.: 2118899-51-5
- Formula:C25H25Cl2FN2O2
- Molecular Weight:475.38
IUPAC Name: (E)-3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid
InChIKey: PSJRZBBUWGIUPM-BBNFHIFMSA-N
SMILES: CC(C)(F)CN1[C@@](C2=C(C=C(C=C2Cl)/C=C/C(O)=O)Cl)([H])C3=C(C[C@H]1C)C4=CC=CC=C4N3
Biological Activity: Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taragarestrant | Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776.
- [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical
Keywords
